J&J pauses COVID-19 vaccine trial over participant’s ‘unexplained illness’

The drugmakers single-shot vaccine candidate is the 4th to go into stage 3 screening in the U.S. Modernas candidate and the one Pfizer is developing with BioNTech both went into stage 3 testing in July. The vaccine AstraZeneca is establishing with the University of Oxford began phase 3 screening in August, but its U.S. trial is presently stopped briefly as its safety is reviewed following a negative reaction in a U.K. trial participant..

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.

Katie Adams –
Tuesday, October 13th, 2020

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.

Johnson & & Johnson started registering participants in its stage 3 vaccine trial Sept. 23, intending to gather 60,000 individuals in the U.S., Mexico, Argentina, Brazil, Chile, Colombia, Peru and South Africa.

The drugmaker told STAT that the research study has been stopped briefly due to “an unexplained disease in a study individual,” however decreased to disclose additional information.

Johnson & & Johnson voluntarily paused the scientific trial for its COVID-19 vaccine prospect Oct. 12 after knowing of an individuals unusual disease, STAT reported.

More short articles on pharmacy: Operation Warp Speed czar: Vaccine approval likely to be looked for around Thanksgiving7 essential uncertainties surrounding the COVID-19 vaccine race3 more drugmakers remember metformin due to carcinogen.

The studys online enrollment system has been closed, and the information and security monitoring board is being gotten in touch with, according to a file sent to outdoors researchers running the trial that was obtained by STAT.

” We must respect this individuals personal privacy,” Johnson & & Johnson informed STAT. “Were also finding out more about this participants disease, and its important to have all the truths before we share additional info.”.